About us
Introducing Elixir
Founded in 2002, Elixir Securities (“Elixir”) is a London-based Corporate Finance boutique specializing in the global life sciences sectors, including pharmaceuticals, healthcare/research services, biotechnology, diagnostics, medtech and biofuels.
Elixir is focused on developing solutions for those public and private companies seeking to develop and execute their growth strategies either in part or entirely in Europe. Elixir operates at the interface between the public and private markets, primarily in the $5m to $50m space (company size), often using novel deal structures to raise capital in difficult circumstances.
This space, specifically, is of growing importance as the lines of demarcation between privately and publicly funded businesses become blurred. Elixir’s principals have considerable experience in both private and public company finance, gained both from the financial markets and the life sciences industry.
Our capabilities are aligned with the sector-specific financial challenges which these companies face. Elixir aims to become a key partner with all of the parties involved in the life sciences space: In every case we aspire to become part of the team, rather than mere advisors.
«Click on the Activity of Interest Below »
«Click on the Activity of Interest Above »
View our track record »
People
Elixir calls on the skills and
experiences of a wide range of people in order to provide the best advice
possible to companies operating across the breadth of the healthcare markets.
In particular Elixir places particular weight on its experiences from
working and running the sort of companies to which we now provide advice.
Elixir also has many years of experience from working in financial services
as ranked Biotech/Healthcare and Pharmaceutical analysts. We therefore
believe that we have achieved a broad-based skill-set within a concentrated
group of professionals.
Meet the team »
Capabilities
We recognize that successful business relationships are the product of a complex interplay of factors including professionalism, empathy, and delivery. Elixir’s principals were formerly ranked analysts and investment bankers with operational experience in the life sciences industry. As scientists, first and foremost, we draw on a wealth of experience to provide our clients with solutions which not only reflect the demands of the financial markets, but also our understanding of the realities of the life sciences world.
‘Primary markets’ capabilities include public and private placements, PIPEs, secondary offerings, IPOs, pre-IPOs, buyouts/ins and special-situation deal structures, such as those which pre-fund corporate “buy-and-build” acquisition strategies. Elixir is also able to undertake Mergers/Acquisitions and product licensing mandates
If you would like to talk to Elixir about a specific project, please click on the button below. The most appropriate person will then contact you directly, to discuss your specific needs.
.